THERAPY DOSSIER · th-5758e02c2f21

Oligonol, a low molecular weight polyphenol of catechin-type monomers and oligomers derived from lychee fruit

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 3

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00731926 ↗PHASE2/PHASE3completed

Effect of Antioxidant (Oligomerized Litchi Fruit Extract) on Endurance Performance in Healthy Men

Exercise Tolerance

Enrolment: 69 · Results not recorded

NCT01162174 ↗PHASE1completed

Effects of Oligonol on Vascular Function and Inflammation in Healthy Men: Double-Blind Dose-Finding Study

Cardiovascular Health

Enrolment: 16 · Results not recorded

NCT03788577 ↗NAcompleted

Impact of Oligonol on Cardiometabolic Risk and Muscular Health: a Randomized Controlled Trial

Muscle Loss · Muscle Weakness · Quality of Life

Enrolment: 120 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26798422 ↗2015Reported benefit

Oligonol Ameliorates CCl4-Induced Liver Injury in Rats via the NF-Kappa B and MAPK Signaling Pathways.

RatChemical/toxinSprague-Dawleyoral10 or 50 mg/kg

Model: Carbon tetrachloride (CCl4)-induced acute hepatic injury

Oral oligonol reduced CCl4-induced histological abnormalities and lowered serum AST and ALT, attenuated inflammatory mediator expression and suppressed NF-kappa B activation and upstream kinase phosphorylation.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…